1,138
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Fluorodeoxyglucose positron emission tomography for detection of tumor recurrence following radiofrequency ablation in retrospective cohort of stage I lung cancer

, , , &
Pages 1-8 | Received 06 Feb 2018, Accepted 15 Apr 2018, Published online: 03 May 2018

References

  • Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):234S–242S.
  • Chan VO, McDermott S, Malone DE, et al. Percutaneous radiofrequency ablation of lung tumors: evaluation of the literature using evidence-based techniques. J Thorac Imaging. 2011;26:18–26.
  • Gomez FM, Palussiere J, Santos E, et al. Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed. Clin Transl Oncol. 2009;11:28–34.
  • Lanuti M, Sharma A, Willers H, et al. Radiofrequency ablation for stage I non-small cell lung cancer: management of locoregional recurrence. Ann Thorac Surg. 2012;93:921–927. [discussion 927–988].
  • Goldberg SN. Radiofrequency tumor ablation: principles and techniques. Eur J Ultrasound. 2001;13:129–147.
  • Steinke K, King J, Glenn D, et al. Radiologic appearance and complications of percutaneous computed tomography-guided radiofrequency-ablated pulmonary metastases from colorectal carcinoma. J Comput Assist Tomogr. 2003;27:750–757.
  • Abtin FG, Eradat J, Gutierrez AJ, et al. Radiofrequency ablation of lung tumors: imaging features of the postablation zone. Radiographics. 2012;32:947–969.
  • Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9:621–628.
  • Kang S, Luo R, Liao W, et al. Single group study to evaluate the feasibility and complications of radiofrequency ablation and usefulness of post treatment position emission tomography in lung tumours. World J Surg Oncol. 2004;2:30.
  • Singnurkar A, Solomon SB, Gonen M, et al. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. J Nucl Med. 2010;51:1833–1840.
  • Wang Y, Brett CW, Muse V, et al. Potential pitfall in the assessment of lung cancer with FDG-PET/CT: Talc pleurodesis causes intrathoracic nodal FDG avidity. Lung Cancer Intl. 2013;2013:683582.
  • Viglianti BL, Wale D, Wong KK, et al. Effects of tumor burden on reference tissue standardized imaging uptake for PET imaging: modification of PERCIST criteria. Radiology. Forthcoming 2018.
  • Alafate A, Shinya T, Okumura Y, et al. The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation. Acta Med Okayama. 2013;67:105–112.
  • Purandare NC, Rangarajan V, Shah SA, et al. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings. Radiographics. 2011;31:201–213.
  • Sharma A, Lanuti M, He W, et al. Increase in fluorodeoxyglucose positron emission tomography activity following complete radiofrequency ablation of lung tumors. J Comput Assist Tomogr. 2013;37:9–14.
  • Bonichon F, Palussiere J, Godbert Y, et al. Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2013;40:1817–1827.
  • Rasmussen F, Madsen HH. Imaging follow-up of RF ablation of lung tumours. Cancer imaging: the official publication of the International. Cancer Imaging Soc. 2011;11 Spec No A:S123–S128.
  • Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 (Suppl 1):122S–150S.
  • Kim SR, Han HJ, Park SJ, et al. Comparison between surgery and radiofrequency ablation for stage I non-small cell lung cancer. Eur J Radiol. 2012;81:395–399.